Biofrontera
BFRI
8 hedge funds and large institutions have $26.2K invested in Biofrontera in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.56% less ownership
Funds ownership: 1.18% → 0.62% (-0.56%)
82% less capital invested
Capital invested by funds: $142K → $26.2K (-$116K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.8K |
| 2 |
JP Morgan Chase
New York
|
+$3.6K |
| 3 |
Morgan Stanley
New York
|
+$873 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$48 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$96.1K |
| 2 |
CSPIA
Cary Street Partners Investment Advisory
Richmond,
Virginia
|
-$219 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9 |
BFRI Hedge Fund Activity: Q4 2023 in Review
8 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRI) for Q4 2023, worth a combined $26.2K — down 82% from $142K a quarter earlier.
Fund positioning in BFRI was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $13.8K. The largest seller was Vanguard Group, exiting entirely with an estimated $96.1K sold.
- 8 institutional investors held Biofrontera (BFRI) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $26.2K of Biofrontera stock for Q4 2023, down 82% quarter-over-quarter.
- 3 funds opened new Biofrontera positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Biofrontera buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $13.8K added.
- The largest Biofrontera seller in Q4 2023 was Vanguard Group, an estimated $96.1K sold.
Based on aggregated 13F filings for Q4 2023.